Based on the provided data and current market conditions, let's analyze whether CHDN is overvalued through a comprehensive analysis:
Technical Analysis
The stock is showing significant weakness with RSI at 25.94 and stochastic RSI at 8.63, indicating oversold conditions. The stock has broken below its 20-day moving average of $122.00 and is trading near the lower Bollinger Band at $113.81, suggesting potential technical support around this level.
Valuation Metrics
Current valuation metrics compared to historical levels:
Metric |
2023 |
2024 |
P/E |
24.61 |
20.21 |
EV/EBITDA |
19.32 |
14.87 |
P/S |
4.17 |
3.28 |
P/B |
11.25 |
N/A |
Fundamental Analysis
The company shows:
- Strong revenue growth of 36% YoY in 2023
- Healthy gross margin expansion to 32.96%
- However, net margin declined to 16.95% from 24.35%
- Current ratio of 0.53 indicates potential liquidity concerns
Analyst Consensus
Recent analyst actions show:
- Price target lowered to $161 from $164 at Stifel
- Price target lowered to $158 from $165 at Wells Fargo
- Consensus price target of $162.00 represents 41% upside potential
Conclusion
CHDN is NOT overvalued at current levels based on:
- Trading at 20.21x P/E, below its 2023 multiple of 24.61x
- EV/EBITDA of 14.87x shows significant compression from 19.32x
- Strong analyst support with consensus upside of 41%
- Recent price weakness has created an attractive entry point
- Technical indicators suggest oversold conditions ripe for reversal